Table 3.
Glucose Clamp Pharmacokinetic and Glucodynamic Parameters Obtained Comparing Infusion of a Comixture of Recombinant Human Hyaluronidase (5 µg/ml) + Insulin Aspart (100 U/ml) versus Pretreatment of the Infusion Site with Recombinant Human Hyaluronidase (150 U [1.25 µg] in 1.0 ml) Followed by Infusion of Insulin Aspart Alone
| Method of administering rHuPH20 | Infusion site age | Early exposure (% of total in first 60 min) | Onset of action (early glucose infusion rate t50%) | Duration of action [AUMC(0–360)/AUC(0–360)] |
|---|---|---|---|---|
| Comixture | Half day | 35% | 35 min | 147 min |
| Comixture | 2.5 days | 51% | 40 min | 133 min |
| Pretreatment | <2 h | 31% | 34 min | 139 min |
| Pretreatment | 1 day | 37% | 32 min | 134 min |
| Pretreatment | 3 days | 32% | 31 min | 146 min |
AUMC, area under the first moment curve.